Wild-Type MIC Distributions and Epidemiological Cutoff Values for Posaconazole and Voriconazole and Candida spp. as Determined by 24-Hour CLSI Broth Microdilution
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
We tested 16,191 strains of Candida against posaconazole and voriconazole, using the CLSI M27-A3 broth microdilution (BMD) method (24-h incubation), in order to define wild-type (WT) populations and epidemiological cutoff values (ECVs). From 2001 to 2009, 8,619 isolates of Candida albicans , 2,415 isolates of C. glabrata , 2,278 isolates of C. parapsilosis , 1,895 isolates of C. tropicalis , 508 isolates of C. krusei , 205 isolates of C. lusitaniae , 177 isolates of C. guilliermondii , and 93 isolates of C. kefyr were obtained from over 100 centers worldwide. The modal MICs (μg/ml) for posaconazole and voriconazole, respectively, were as follows: for C. albicans , 0.016 and 0.007; for C. glabrata , 0.5 and 0.06; for C. parapsilosis , 0.06 and 0.007; for C. tropicalis , 0.03 and 0.015; for C. krusei , 0.25 and 0.12; for C. lusitaniae , 0.03 and 0.007; for C. guilliermondii , 0.12 and 0.03; and for C. kefyr , 0.06 and 0.007. The ECVs (μg/ml [% of isolates that had MICs equal to or less than the ECV]) for posaconazole and voriconazole, respectively, were as follows: 0.06 (98.5) and 0.03 (98.9) for C. albicans , 2 (96.2) and 0.5 (90.4%) for C. glabrata , 0.25 (99.3) and 0.12 (97.9) for C. parapsilosis , 0.12 (97.6) and 0.06 (97.2) for C. tropicalis , 0.5 (99.8) and 0.5 (99.4) for C. krusei , 0.12 (95.6) and 0.03 (96.6) for C. lusitaniae , 0.5 (98.9) and 0.25 (98.3) for C. guilliermondii , and 0.25 (100.0) and 0.015 (100.0) for C. kefyr . In the absence of clinical breakpoints (CBPs) for posaconazole, these WT distributions and ECVs will be useful in surveillance for emergence of reduced susceptibility to posaconazole among Candida spp. Whereas a CBP for susceptibility of ≤1 μg/ml has been established for voriconazole and all species of Candida , it is notable that ECVs for this agent range from 10- to >100-fold lower than the CBP, depending on the species of Candida . The CBP is inadequate in detecting the emergence of voriconazole resistance among most Candida species encountered clinically. The CBPs for voriconazole should be reassessed, with consideration for development of species-specific CBPs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Morrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286
Garey, K. W., Rege, M., Pai, M. P., Mingo, D. E., Suda, K. J., Turpin, R. S., & Bearden, D. T. (2006) · Clinical Infectious Diseases · doi:10.1086/504810 · Cited by 1,171 · cited 1×
“Given the facts that a shorter incubation period is more efficient and practical for use in the clinical laboratory (16, 36) and that research has shown that early/ correct antifungal treatment has a positive effect on outcomes for patients with candidemia (5, 6, 12, 19, 20, 23, 27, 29, 33, 53), the CLSI has determine…”
MethodKullberg, B., Sobel, J., Ruhnke, M., Pappas, P., Viscoli, C., Rex, J., Cleary, J., Rubinstein, E., Church, L., Brown, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67490-9 · Cited by 521
Has antifungal susceptibility testing come of age
Rex, J. H., & Pfaller, M. A. (2002) · Clinical Infectious Diseases · doi:10.1086/342384 · Cited by 361 · cited 1×
“the “90-60 rule” (41) to arrive at the following CBPs: suscep-”
BackgroundSelf-citationAlly, R., Schürmann, D., Kreisel, W., Carosi, G., Aguirrebengoa, K., Dupont, B., Hodges, M., Troke, P., Romero, A. J., & the Esophageal Candidiasis Study Group (2001) · Clinical Infectious Diseases · doi:10.1086/322653 · Cited by 331
Pfaller, M. A., Diekema, D. J., Rex, J. H., Espinel-Ingroff, A., Johnson, E. M., Andes, D., Chaturvedi, V., Ghannoum, M. A., Odds, F. C., Rinaldi, M. G., et al. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.3.819-826.2006 · Cited by 258
Self-citationTreatment-related risk factors for hospital mortality in Candida bloodstream infections
Labelle, A. J., Micek, S. T., Roubinian, N., & Kollef, M. H. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e31818b3477 · Cited by 181 · cited 1×
“Given the facts that a shorter incubation period is more efficient and practical for use in the clinical laboratory (16, 36) and that research has shown that early/ correct antifungal treatment has a positive effect on outcomes for patients with candidemia (5, 6, 12, 19, 20, 23, 27, 29, 33, 53), the CLSI has determine…”
MethodZilberberg, M. D., Kollef, M. H., Arnold, H., Labelle, A., Micek, S. T., Kothari, S., & Shorr, A. F. (2010) · BMC Infectious Diseases · doi:10.1186/1471-2334-10-150 · Cited by 128
Cited by
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Pfaller, M. A., & Diekema, D. J. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00937-12 · Cited by 484
Self-citationWisplinghoff, H., Ebbers, J., Geurtz, L., Stefanik, D., Major, Y., Edmond, M. B., Wenzel, R. P., & Seifert, H. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.09.005 · Cited by 293
Pfaller, M. A., Espinel-Ingroff, A., Canton, E., Castanheira, M., Cuenca-Estrella, M., Diekema, D. J., Fothergill, A., Fuller, J., Ghannoum, M., Jones, R. N., et al. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00248-12 · Cited by 174
“(25) established epidemiological cutoff values (ECVs) to differentiate wildtype (WT) strains (those without mutational or acquired resistance mechanisms) from non-WT strains (those having mutational or acquired resistance mechanisms) as a means of tracking the emergence of reduced susceptibility to posaconazole among…”
BackgroundSelf-citationPfaller, M. A., Andes, D., Arendrup, M. C., Diekema, D. J., Espinel-Ingroff, A., Alexander, B. D., Brown, S. D., Chaturvedi, V., Fowler, C. L., Ghannoum, M. A., et al. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2011.03.002 · Cited by 130
Self-citation
Metadata
- Authors
- Pfaller, M. A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., & Diekema, D. J.
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2011-02
- Volume
- 49
- Issue
- 2
- Pages
- 630-637
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- OpenAlex
- W2058909715
- Cited by
- 61
- References
- 9
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Wild-Type MIC Distributions and Epidemiological Cutoff Values for Posaconazole and Voriconazole and Candida spp. as Determined by 24-Hour CLSI Broth Microdilution. https://app.cochat.ai/papers/10.1128/jcm.02161-10
- The paper
- Pfaller, M. A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2011). Wild-Type MIC Distributions and Epidemiological Cutoff Values for Posaconazole and Voriconazole and Candida spp. as Determined by 24-Hour CLSI Broth Microdilution. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.02161-10
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.